Richard Kaplan

68.3k citations

173 papers · 46.0k indexed · 5 hit papers · h-index 48

Impact in

Oncology top 0.01%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research

Papers in

Oncology 68
- Colorectal Cancer Treatments and Studies 42
- Cancer Treatment and Pharmacology 22
Reproductive Medicine 19
- Ovarian cancer diagnosis and treatment 19

Co-authors: Susan G. Arbuck Larry Rubinstein Michaele C. Christian Margaret Mooney Lalitha Shankar P. Therasse Janet Dancey Lawrence H. Schwartz
Journals: Journal of Clinical Oncology (35 papers)Annals of Oncology (13 papers)Cancer (8 papers)JNCI Journal of the National Cancer Institute (7 papers)Neurosurgery (5 papers)
Partner nations: United Kingdom United States Canada

In The Last Decade

Richard Kaplan

168 papers receiving 45.2k citations

Hit Papers

5 papers align trajectories log scale

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study 2017 · 2.2k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 The Lancet
2014 Clinical Cancer Research
2008 European Journal of Cancer
2003 Journal of Clinical Oncology
2000 JNCI Journal of the National Cancer Institute

Peers

Countries citing papers authored by Richard Kaplan

Since Specialization

Citations

This map shows the geographic impact of Richard Kaplan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Kaplan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Kaplan more than expected).

Fields of papers citing papers by Richard Kaplan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Kaplan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Kaplan. The network helps show where Richard Kaplan may publish in the future.

Co-authors

The 25 scholars most cited alongside Richard Kaplan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Richard Kaplan Line = papers co-authored together Richard Kaplan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Apollo (University of Cambridge) ·Bhavna Oza, Tim Eisen, Eleni Frangou, Grant D. Stewart, Axel Bex, A.W.S. Ritchie, Richard Kaplan, J. P. Lipton, Ian D. Davis, Martin R. Stockler, Laurence Albigès, Bernard Escudier, James Larkin, Steven Joniau, Barry W. Hancock, Gregers G. Hermann, Joaquim Bellmunt, Mahesh Parmar, Patrick Royston, Angela Meade	2022	10
2	The risks you can’t foresee: what to do when there’s no playbook Oxford University Research Archive (ORA) (University of Oxford) ·Richard Kaplan, Tiffany D. Putri, Anette Mikes	2020	3
3	Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants European Journal of Cancer ·А.Л. Максимов, Tim Maughan, Richard Kaplan, Philip Law, Richard S. Houlston, Valentina Escott‐Price, Jeremy P. Cheadle	2019	6
4	What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial PubMed ·Nicola Jane Lawrence, Andrew Martin, Ian D. Davis, Sally Binks, Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Richard Kaplan, J. P. Lipton, A.W.S. Ritchie, Angela Meade, Tim Eisen, Prunella Blinman, Martin R. Stockler	2018	4
5	Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? Annals of Oncology ·Prunella Blinman, 聡篠崎, Andrew Martin, Sally Binks, Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Richard Kaplan, A.W.S. Ritchie, Angela Meade, Tim Eisen, Martin R. Stockler	2017	12
6	ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis Annals of Oncology ·Rahmath Fida, Iain A. McNeish, Andrew Dean, David Gallardo, T. A. Carter, Dearbhaile M. O’Donnell, Jane Hook, C. Coyle, Sarah P. Blagden, James D. Brenton, Raj Naik, Timothy Perren, Sudha Sundar, Adrian Cook, Elizabeth C James, Ann Marie Swart, Sally Stenning, Richard Kaplan, Jonathan A. Ledermann	2017	38
7	BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer Clinical Cancer Research ·А.Л. Максимов, Christopher G. Smith, Tim Maughan, Richard Kaplan, Valentina Escott‐Price, Jeremy P. Cheadle	2016	35
8	Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study British Journal of Cancer ·Tal Grenader, Stephen Nash, Richard Adams, Richard Kaplan, David J. Fisher, Tim Maughan, John Bridgewater	2016	55
9	Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival Clinical Cancer Research ·Christopher G. Smith, David J. Fisher, Rebecca Harris, Tim Maughan, Amanda I. Phipps, Susan D. Richman, Michel Seymour, Ian Tomlinson, Dan Rosmarin, David Kerr, Andrew T. Chan, Ulrike Peters, Polly A. Newcomb, Shelley Idziaszczyk, Hannah D. West, Angela Meade, Richard Kaplan, Jeremy P. Cheadle	2015	16
10	Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies Clinical Cancer Research ·Sabine Venderbosch, Irıs D. Nagtegaal, Tim Maughan, Christopher G. Smith, Jeremy P. Cheadle, David J. Fisher, Richard Kaplan, Philip Quirke, Michel Seymour, Susan D. Richman, Gerrit A. Meijer, Bauke Ylstra, Daniëlle A.M. Heideman, Anton F. J. de Haan, Cornelis J.A. Punt, Miriam Koopman Hit paper breakdown →	2014	534
11	Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab Clinical Cancer Research ·Christopher G. Smith, David J. Fisher, Bart Claes, Tim Maughan, Shelley Idziaszczyk, Gilian Peuteman, Rebecca Harris, Michelle D. James, Angela Meade, Bharat Jasani, Richard Adams, Sarah Kenny, Richard Kaplan, Diether Lambrechts, Jeremy P. Cheadle	2013	86
12	A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT Annals of Oncology ·Jeremy P. Cheadle, 貝沼関志, David I. Fisher, Tim Maughan, Valentina Moskvina, Angela Meade, Hannah D. West, Richard Kaplan	2010	1
13	High throughput somatic profiling of the Ras-Raf-MAP and PI3K-PTEN-Akt pathways in advanced colorectal cancer and correlations with response to cetuximab Annals of Oncology ·Christopher G. Smith, Bart Claes, David I. Fisher, Hussein Alqarni, Richard Kaplan, Angela Meade, Diether Lambrechts, Tim Maughan, Jeremy P. Cheadle	2010	1
14	THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL Annals of Oncology ·Ayman Madi, A. Borangiu, Richard Adams, Michel Seymour, Angela Meade, J Cassidy, Meredith Eldridge, Sarah Kenny, Richard Kaplan, Jiamei Cao	2010	2
15	RESPONSE: Re: Brain and Other Central Nervous System Cancers: Recent Trends in Incidence and Mortality JNCI Journal of the National Cancer Institute ·Jos Vermeulen, H Groen, Chunling Wang, Jan Christoph Elfert, Y K AlGanime, Richard Kaplan, José Marín-Roig Ramón	1999	15
16	Effect of Back Supports on Back Strength in Patients With Osteoporosis: A Pilot Study Mayo Clinic Proceedings ·Richard Kaplan, Mehrsheed Sinaki, Kang Rong-qiu	1996	43
17	Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non‐Hodgkin's lymphoma: Cancer and leukemia group B study 8351 Medical and Pediatric Oncology ·Mary Ellen Rybak, James R. Anderson, Richard Kaplan, Daniel R. Budman, Vincent Vinciguerra, Arlan J. Gottlieb	1993	2
18	Neoadjuvant therapy in cancer treatment Cancer ·Edward L. Trimble, Richard S. Ungerleider, J. B. Liu, Richard Kaplan, Ellen G. Feigal, Malcolm A. Smith, Bianca Diffidenti, Michael Friedman	1993	43
19	PRELIMINARY-OBSERVATIONS ON THE EFFECTS OF DIMETHYLSULFOXIDE ON THE METABOLISM AND DISTRIBUTION OF ADRIAMYCIN UCL Discovery (University College London) ·Richard Kaplan, (unknown), (unknown), Michael Salcman, Joseph Aisner, (unknown), (unknown)	1981	2
20	Effects of Visual Feedback Delay on Simulated Automobile Steering Journal of Motor Behavior ·Karl U. Smith, Richard Kaplan	1970	4

About Richard Kaplan

Richard Kaplan is a scholar working on Oncology, Reproductive Medicine, Pulmonary and Respiratory Medicine, Genetics and Cancer Research, having authored 173 papers that have together received 46.0k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (42 papers), Cancer Treatment and Pharmacology (22 papers), Ovarian cancer diagnosis and treatment (19 papers), Genetic factors in colorectal cancer (18 papers), Glioma Diagnosis and Treatment (17 papers), Cancer Genomics and Diagnostics (17 papers), Renal cell carcinoma treatment (15 papers) and Prostate Cancer Diagnosis and Treatment (15 papers). The work is most often cited by research in Oncology (22.4k citations), Pulmonary and Respiratory Medicine (20.2k citations), Hepatology (4.2k citations), Cancer Research (6.8k citations) and Radiology, Nuclear Medicine and Imaging (7.5k citations). Richard Kaplan has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Susan G. Arbuck, Larry Rubinstein, Michaele C. Christian, Margaret Mooney, Lalitha Shankar, P. Therasse, Janet Dancey, Lawrence H. Schwartz, Lori E. Dodd and E. Eisenhauer. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer, JNCI Journal of the National Cancer Institute and Neurosurgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact